- Policy
- AZ-China joint venture Dizal tests drug in Korea
- by Lee, Tak-Sun Jun 8, 2020 06:15am
- Dizal Pharma, a joint venture company by AstraZeneca and a Chinese firm, is initiating a clinical trial in Korea on non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) or human epidermal growth receptor 2 (HER2) mutation. The pharmaceutical industry is paying a close attention on the Chinese company
- Company
- Customized Rx considering the patient's condition is needed
- by Eo, Yun-Ho Jun 8, 2020 06:13am
- The need for patient-specific prescriptions is emerging in the field of obesity treatment. At the recently held 'Saxenda e-Class' (Saxenda.livesympo.com), Professor Hye Jin Chun of the dept. of Family Medicine at Cha University Bundang Medical Center had a time to cover information about treatment for obesity. On this day, Professor Hye J
- Policy
- The copayment of Remdesivir is supported by the government
- by Kim, Jung-Ju Jun 8, 2020 06:11am
- While the government announced that it would make special imports of Remdesivir, which is being evaluated as COVID-19 treatment, the quarantine authorities said that the cost of treatment is likely to be paid by the NHIS, and the patient's cost of liability is likely to be paid by the government. Eun-kyung Chung, the head of the Central Di
- Policy
- Court dismisses request to revoke Galvus IMD approval
- by Lee, Tak-Sun Jun 8, 2020 06:11am
- Novartis’ request to revoke Korea’s Ministry of Food and Drug Safety (MFDS) approving Hanmi Pharmaceutical’s Vildagle (vildagliptin hydrochloride) has reportedly been dismissed. In May, Novartis has filed a litigation to cancel a drug approval on Vildagle 50 mg tablet, claiming the Korean-made drug did not fulfill the duty to notify
- Company
- Celltrion, begins development of Insulin pen biosimilar
- by An, Kyung-Jin Jun 8, 2020 06:11am
- Celltrion is working with a domestic medical device company to develop an insulin biosimilar. The goal is to secure cost competitiveness and lower dependence on imports by developing a pen-type insulin injection for the first time in Korea. Celltrion’s insulin pipeline was selected as a state-designated project by the Korea Evaluation Ins
- Policy
- Abbvie’s Rinvoq was approved
- by Lee, Tak-Sun Jun 5, 2020 06:10am
- Another oral rheumatoid arthritis drug has been approved in Korea. It is Abbvie’s Rinvoq sustained-release tablet 15mg (Upadacitinib). The competing drugs include Pfizer’s Xeljanz (Topacitinib), Lilly' Olumiant (Baricitinib), and Astellas' Smyraf (Peficitinib). On the 4th, the MFDS approved Abbvie’s Rinvoq 15mg as a new drug. It is u
- Company
- Unpredictable Cancer Committee make all kinds of decisions
- by Eo, Yun-Ho Jun 5, 2020 06:10am
- The expression on all the pharmaceutical companies accepting the final outcome varied as the meeting concluded. But for sure, no one had a perfect game. On June 3, Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee was convened to discuss two immunotherapies, two poly ADP-ribose polymerase (PARP) inhibiting t
- Company
- General Hospitals to prescribe AbbVie Skyrizi with coverage
- by Eo, Yun-Ho Jun 5, 2020 06:10am
- General hospitals are ready to prescribe now listed Skyrizi, the fourth interleukin inhibitor in the Korean market. Pharmaceutical industry sources reported drug committees (DC) at Korea University Ansan Hospital, Soonchunhyang University Bucheon Hospital, Design Hospital, Gangnam Severance Hospital, Dankook University Hospital, Hallym U
- Policy
- Remdesivir's special import was decided
- by Lee, Tak-Sun Jun 5, 2020 06:10am
- The special import of Gilead’s Remdesivir was decided. It will be used in severely hospitalized patients infected with the COVID-19. The MFDS (Minister Lee Eui-kyung) decided to import special cases for Remdesivir, which is being developed as a treatment for COVID-19, and accordingly, the KCDC (Director Eun-Kyung Jung), announced on the 3
- Policy
- COVID-19 vaccine by Inovio was first approved in Korea
- by Lee, Tak-Sun Jun 5, 2020 06:09am
- COVID-19 vaccine is the first clinical trial approved in Korea. It is a vaccine candidate developed by Inovio of the United States and is conducted by theInternational Vaccine Institute (IVI). On the 2nd, the MFDS approved phase I/IIa of IN0-4800, a candidate for COVID-19 vaccine, applied by the IVI. In clinical trials, the safety, tole
